I n the US, %735 000 myocardial infarctions and 795 000 strokes occur annually, resulting in %500 000 deaths including %130 000 deaths from stroke and %370 000 deaths from coronary disease. 1, 2 In 2010, ischemic heart disease was the leading cause of life lost in the United States at 7.2 million life years with stroke third at 1.9 million years. 3 Healthy People 4 2020 goals include reducing deaths from heart disease and stroke 20%. 5 Hypercholesterolemia is a major, modifiable risk factor for coronary heart disease (CHD) and stroke. 6 Statins are beneficial for the primary and secondary prevention of fatal and nonfatal CHD and stroke. 7, 8 The American College of Cardiology/American Heart Association (ACC/AHA) 2013 Cholesterol Guideline, hereafter the 2013 Cholesterol Guideline, would treat %12.8 million additional adults aged 40 to 75 years old for hypercholesterolemia than recommended in the National Cholesterol Education Program/Adult Treatment Panel-3 guideline (NCEP/ATP-3). 9 Moreover, the atherosclerotic cardiovascular disease (ASCVD) risk calculator in the 2013 Cholesterol Guideline is more strongly associated with coronary calcium scores and cardiovascular outcomes than is the CHD risk equation in ATP-3. 10 These observations suggest that cardiovascular health could be improved and Healthy People 2020 goals advanced by implementing the 2013 Cholesterol Guideline. A prior analysis indicated that full implementation of the 2013 Cholesterol Guideline would prevent an additional %475 000 cardiovascular events over 10 years compared with full implementation of the Adult Treatment Panel (ATP)-3 Guideline. 9 A cost-effectiveness analysis suggested that lowering the threshold for intervention from a 10-year ASCVD risk (ASCVD 10 ) from ≥7.5% to ≥3.0% would prevent an additional 161 650 ASCVD events over 10 years and was cost effective, especially with low-cost statins. 11 In both reports, only adults aged 40 to 75 years were included, and statins were assumed to reduce CHD by 25% and stroke by 17%, given a 39-mg/dL reduction in low-density lipoprotein cholesterol (LDL-C).
The 2013 Cholesterol Guideline extends to a broader age range than 40 to 75 years for adults with clinical atherosclerotic cardiovascular disease or low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL. 6 Moreover, the percentage and absolute reduction in LDL-C are dose dependent with high-intensity statins more effective than moderate-intensity statins in reducing ASCVD, 6, 8, [12] [13] [14] [15] [16] although adverse effects also increase. [16] [17] [18] [19] The current and previous cholesterol guidelines also identified a favorable risk:benefit ratio for statins in adults aged ≥75 years with clinical ASCVD. 6, 20, 21 Given the importance of ASCVD prevention, we examined the impact of implementing the 2013 Cholesterol Guideline on 2 key outcomes. One outcome was to estimate the number of ASCVD events that could be prevented in the United States by providing statins to currently untreated but statin-eligible adults 21 to 79 years old. A second outcome was to calculate absolute risk reduction (ARR) and 10-year number needed-to-treat (NNT) to prevent a major ASCVD event. This information is important for assessing clinical resource requirements and risk:benefit ratio. Study findings have potentially important implications for healthcare delivery, policy, and payment to enhance cardiovascular health promotion and disease prevention.
Methods
The National Health and Nutrition Examination Surveys (NHANES) assess health and nutritional status in a representative sample of the US noninstitutionalized civilian population. All adults provided written consent, which was approved by the National Center for Health Statistics. 22, 23 Participants included adults aged 21 to 79 years in NHANES 2007-2012 with ≥1 recorded blood pressure (BP) and a complete lipid profile.
Statin use was determined from medications reportedly taken in the prior 30 days and a match to known statins.
Race/ethnicity was determined by self-report and separated into non-Hispanic white (white), non-Hispanic black (black), Hispanic ethnicity, and other.
BP was measured and analyzed according to NHANES guidelines. [22] [23] [24] Hypertension was defined by systolic BP ≥140
and/or diastolic BP ≥90 mm Hg or positive response to "Are you currently taking prescribed medication to lower your BP?" Systolic BP of 60 to 300 mm Hg and diastolic BP of 30 to 240 mm Hg were accepted as valid. Prevalent diabetes mellitus included (1) diagnosed diabetes mellitus defined by positive response(s) to ≥1 question, "Have you ever been told by a doctor that you have diabetes mellitus ?" or "Are you now taking insulin?" or "Are you now taking diabetic pills to lower your blood sugar?" and (2) undiagnosed diabetes mellitus was defined by negative responses to the questions and fasting glucose ≥126 mg/dL or glycosylated hemoglobin ≥6.5%.
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Lipid/Lipoprotein Values
As shown in Figure 1 , fewer than half of adult participants in NHANES provided fasting blood samples. Total cholesterol and high-density lipoprotein cholesterol (HDL-C) were measured on all participants regardless of fasting status, whereas triglycerides were measured and LDL-C calculated only from fasting samples. For patients with triglyceride levels >400 mg/dL (n=128, representing 3 627 587 US adults [aged 21-79 years]), LDL-C was not calculated. Total cholesterol of 40 to 800 mg/dL, HDL-C of 2 to 140 mg/dL, LDL-C of 20 to 700 mg/dL, and triglycerides of 20 to 12 000 mg/ dL were accepted as valid.
Inclusion and Exclusion Criteria
Adult men and women aged 21 to 79 years were included with a valid BP and complete lipid profile including calculated LDL-C. Exclusion criteria were self-reported congestive heart failure and estimated glomerular filtration rate <15 mL/1.73 m 2 per minute. 5 Chronic kidney disease was defined by estimated glomerular filtration rate of 15 to 59 mL/1.73 m 2 per minute. 26 Statin eligibility by the 2013 ACC/AHA Cholesterol Guideline was defined as summarized in Table 1 . 6 For the main analysis, we assumed that 75% of adults without diabetes mellitus and ASCVD 10 ≥7.5% (1A for moderate-to high-intensity statin) and 50% with diabetes mellitus and ASCVD 10 ≥7.5% (IIaB for high-intensity statin) would receive high-intensity statin. Assumptions reflect arbitrary estimates of how informed clinicians would balance recommendations and benefit:risk information. For every 2 additional cases of incident diabetes mellitus with highversus moderate-intensity statin in patients with CHD, 6.5 fewer major vascular events occur. 16 Dr Robinson, co-author of the 2013 Cholesterol Guideline, summarized safety data on statin therapy, 14, 27, 28 which indicated that the 5-year number needed-to-harm (NNH) was %167 for moderate-intensity and 63 for high-intensity statin therapy. 19 With regard to rhabdomyolysis, a nonsignificant increase with high-versus moderate-intensity statin was noted in 1 meta-analysis (odds ratio 1.66, P=0.326). 18 Given uncertainty over what intensity statin therapy clinicians would prescribe, a sensitivity analysis was performed for these 2 groups by varying the percentages on moderate-and high-intensity statins from 0% to 100%.
Estimated Decline in ASCVD 10 With Statin Therapy
Assumptions included (1) for each 39-mg/dL decline in LDL-C, ASCVD events would fall 21% for ASCVD 10 ≥20% and 33% for ASCVD 10 <20% 15 ; (2) LDL-C would fall 33% with moderate-intensity and 51% with high-intensity statin therapy, that is, the conservative end of the estimated 30% to <50% LDL-C reduction with moderate-intensity and ≥50% decline with high-intensity statins 6, 29 ; and (3) for patients with prior stroke or myocardial infarction in whom ASCVD 10 is not calculated, a 39% 10-year risk was assigned. In subjects with angina or transient ischemic attack, a 10-year risk of 31.5% was assigned. Estimates were derived as follows. Adults with clinical CHD have a ≥26% 10-year risk of another CHD event.
Patients with CHD risk equivalent status, excluding diabetes mellitus, 6 have a 10-year CHD risk of >20%. 20, 30, 31 Respective risks of 26% and 21% were multiplied by 1.5, which assumes ASCVD 10 event rates were 50% greater than 10-year CHD risk alone. This assumption is conservative, as annual numbers of strokes (%795 000) and myocardial infarctions (%735 000) in the United States are similar.
1,2 ASCVD 10 , while not required for treating adults aged 21 to 79 years with LDL-C ≥190 mg/dL, 6 was calculated to estimate absolute risk reduction (ARR) and number neededto-treat (NNT). The ACC/AHA ASCVD risk calculator accepts ages 20 to 79 years and limits total cholesterol values to a maximum of 320 mg/dL. In NHANES 2007-2012, 0.59% of adults aged 21 to 79 years in the fasting sample used for this analysis had total cholesterol levels of >320, and all of them had LDL-C levels of ≥190 mg/dL. Total cholesterol values >320 were entered as 320 in the ASCVD risk calculator. 
Data Reporting and Analysis
SAS Enterprise Guide 7.1 was used for all analyses and accounts for complex sampling characteristics of NHANES. One-half of NHANES participants were studied in the morning and were instructed to fast at least 9 hours before their examination. Triglyceride and calculated LDL-C values are provided only for the fasting participants studied in the morning. Because fasting is an important defining characteristic of subjects in our analysis, the fasting sample weight, WTSAF2YR, was used. Descriptive statistics including mean and SE were generated. Wald's F test was applied for continuous variables, and the Rao-Scott modified v 2 test was used for categorical variables.
ASCVD reduction was calculated with the use of PROC SURVEYMEANS. Absolute risk reduction (ARR) and number needed-to-treat (NNT) were calculated using PROC SURVEY-MEANS. Two-sided P<0.05 were accepted as significant. Continuous variables (age) are presented as meanAE1 SE. Categorical variables are presented as NHANES sample number (n) and percentage (%) of US population represented by NHANES sample number. The sum of n-values for participant subgroups on variables, such as visits and education, do not always equal overall NHANES sample N because of missing data. Sample weights on subjects with data were adjusted by NHANES so that summation of subgroup percentages reflect 100% of the US population N for that column, such as taking statins, no statin therapy, statin eligible, and statin ineligible. ASCVD indicates atherosclerotic cardiovascular disease; Educ, highest education level attained; FPL, federal poverty level; N, number represented in US population by NHANES sample; NHANES, national health and nutrition examination surveys; OG, other government. *Non-Hispanic black.
Results
The process for selecting adults for statin eligibility and the number of adults in each statin-eligible group are provided in Figure 1 . (1) were older and more likely to be male and white, (2) more often had health insurance, (3) had incomes ≥200% of the federal poverty level, and (4) had more healthcare visits in the previous year, higher body mass indices, and more prevalent obesity, hypertension, diabetes mellitus, stage 3 to 4 chronic kidney disease, clinical ASCVD, systolic BP, and triglycerides but lower diastolic BP, total cholesterol, LDL-C, and HDL-C levels and fewer cigarette smokers (Tables 2 and 3 ).
Comparing Statin-Eligible and -Ineligible Adults
Of an estimated 175.9 million adults not reporting statin use, 44.8 million (25.5%) were statin eligible by the 2013 Cholesterol Guideline. 3 Compared with statin-ineligible adults, the statin-eligible group (1) was older, more often male and white or black, and less often Hispanic; (2) had lower educational attainment but similar incomes; (3) more often had health insurance; (4) reported more healthcare visits; (5) more often had hypertension, diabetes mellitus, and chronic kidney disease and smoked cigarettes; and (6) had higher body mass index, systolic and diastolic BP, total cholesterol and LDL-C, and triglycerides but lower HDL-C (Tables 2 and 3 ).
Estimates of ASCVD Prevention in Statin-Eligible Adults Not Taking Statins
Data are provided for the number of adults in the various groups of statin-eligible adults, (1) Figure 2 ). Adults without diabetes mellitus and ASCVD 10 risk ≥7.5% have a 1A recommendation for moderate-to high-intensity statins. The absolute number of ASCVD events prevented and ARR increase as the proportion of adults on high-intensity statins increases (Table 5) , whereas NNT falls ( Figure 2 ).
Discussion
Statins are recommended for the primary and secondary prevention of CHD and stroke. 10 , n indicates number of ASCVD events over 10 years with statins; ⊕DM, DM present; ∅DM, DM absent; ∅Statin ASCVD 10 , %, 10-year ASCVD risk without a statin; ∅Statin ASCVD 10 , n, number of ASCVD events over 10 years without a statin; ARR, absolute risk reduction; DM, diabetes mellitus; NNT, 10-year number needed-to-treat to prevent an ASCVD event; RRR, relative risk reduction. *Fifty percent of patients with (⊕) diabetes mellitus (DM) and ASCVD 10 ≥7.5% receive high-intensity and 50% receive moderate-intensity statins. † Seventy-five percent of patients without (∅) diabetes mellitus receive high-intensity and 25% receive moderate-intensity statins. ‡ Includes ASCVD, LDL ≥190, and patients with and without diabetes mellitus and 10-year ASCVD risk (ASCVD 10 ) ≥7.5% and excludes lower-risk participants with (⊕) diabetes mellitus (DM) and ASCVD 10 <7.5% and without (∅) diabetes mellitus (DM) and ASCVD 10 5-7.4%. § Includes only lower risk participants with diabetes mellitus and ASCVD 10 <7.5% and without diabetes and ASCVD 10 5-7.4%. efficient for untreated, statin-eligible adults with 10-year ASCVD risk <7.5%, that is, treating 12.6 million adults in this group would prevent %256 147 events over 10 years or 25 615 annually, with ARR of 2.0% and 10-year NNT of 49. The feasibility of identifying and treating 100% of statineligible but untreated adults is low. As an initial step, treating 50% of untreated, statin-eligible adults would also have a positive impact on Healthy People 2020 goals for cardiovascular disease prevention and is credible for several reasons. First, 2 of 3 statin-eligible but untreated adults report ≥2 healthcare visits annually (Table 2) , which indicates opportunities for assessing ASCVD risk and statin eligibility. Second, 80% are insured, which suggests some financial support for screening and treatment. Third, treating half of statin-eligible adults and continuing treatment in those currently on statins would bring statin therapy to 71% of statin-eligible adults. This is comparable to the proportion of all adults with hypertension receiving pharmacotherapy since 2007-2008. 22 Fourth, the majority of statin-eligible but untreated adults also have hypertension with the majority receiving treatment and having ≥2 healthcare visits annually. 22 Fifth, most statins are available as generics with several on discount formularies at <$50/year. 33 Individuals prescribed generic statins experience fewer cardiovascular events and deaths than do individuals prescribed proprietary statins, 34 which suggests the former are more likely than the latter to obtain and take statin medications. Sixth, the percentage of adults taking statins is growing faster than percentages of adults taking antihypertensive medications; that is, the prescribing gap between statins and antihypertensive medications is closing. 35 The points provided could support a more ambitious target than treating 50% of untreated, statin-eligible adults. Yet, the 50% target is an important step in moving to even higher treatment levels. The impact of raising the percentage of statin-eligible adults taking statins from 50% to 75% is enumerated in Table 4 . Our principal analysis assumed that among adults with ASCVD ≥7.5%, 50% of those with diabetes mellitus would receive moderate-intensity and the other would receive 50% high-intensity statin. For the subset without diabetes mellitus, 25% were estimated to receive moderate-and 75% to receive high-intensity statin. Since those were only estimates, sensitivity analyses were conducted, which varied the proportion taking moderate-and high-intensity statins from 0% to 100%. ARR and the number of ASCVD events prevented rose as the proportion taking high-intensity statins increased, whereas the NNT to prevent an ASCVD event fell (Table 5 , Figure 2 ).
Cost-effectiveness of statin therapy, while not the focus of our report, is relevant in extending treatment to millions of additional statin-eligible patients. The cost per quality adjusted life-year for adults with 10-year ASCVD 10 risk of Figure 2 . Absolute risk reduction (ARR) in 10-year risk for atherosclerotic cardiovascular disease (ASCVD) 10 and number needed-to-treat (NNT) to prevent an ASCVD event are depicted for adults with and without diabetes mellitus and with ASCVD 10 ≥7.5%. The data points reflect changes in ARR and NNT as the proportion of individuals taking moderate-dose (MD) and highdose (HD) statins varies from 0% to 100% in 25% increments.
7.5% to <10% was estimated at $37 000. 10 Lowering the treatment threshold further to an ASCVD 10 of 4.0% raised the cost/quality-adjusted life-year to $81 000. Treating all adults ≥75 years old with ASCVD 10 ≥7.5% led to a cost estimate of $25 200 per disability-adjusted life-year. 36 The incremental cost-effectiveness ratio per quality-adjusted lifeyear for high-versus moderate-dose statins was <$50 000, a commonly accepted threshold for cost-effectiveness, assuming a cost differential of <$1.70/day between the 2 statin doses. 37 Safety is another important consideration when increasing the proportion of adults receiving statin therapy. Dr Robinson, co-author of the 2013 Cholesterol Guideline, 6 summarized safety data on statin therapy, 14, 27, 28 which indicated that the 5-year NNH was %167 for moderate-and 63 for high-intensity statin therapy. 19 With regard to the risk-to-benefit considerations with high-versus moderate-intensity statin therapy, and assuming a linear relationship between 1-and 5-year risk, the 5-year NNT in adults with CHD taking high-versus moderate-intensity statin is 31 to prevent a major vascular event versus an NNH of 100 for diabetes mellitus. 15 Analyses from JUPITER indicate that statin-related diabetes mellitus reflects a shortening of the latent period from prediabetes to diabetes mellitus by a few weeks. In JUPITER, only minimal changes in the fasting glucose and glycosylated hemoglobin values were observed among all statin-treated participants. 27 Limitations include a small sample of the US civilian population, partially explained by missing LDL-C in over half of NHANES adults as previously noted (Figure 1) . 22 Health care is dynamic, and data from 2007 to 2012 may not reflect current realities. The potential for ASCVD prevention is limited by clinical barriers, such as lack of data to assess eligibility and failure to assess eligibility when data are available or to prescribe statins when appropriate for ASCVD risk. Patients may fail to fill prescriptions or persist in taking statins, yet substantial persistence with statin therapy at 3 years was documented. 38 And, widely available, low-cost generic statins improve outcomes relative to proprietary statins. 33, 34 In summary, Healthy People 2020 aims to reduce CHD and stroke by 20%. 5 Our estimates suggest that implementing the 2013 Cholesterol Guideline in all statin-eligible adults, or %44.8 million individuals, would accomplish >75% of the Healthy People 2020 annual goal for ASCVD prevention. Implementing the 2013 Cholesterol Guideline in all statineligible adults with ASCVD 10 ≥7.5% could achieve %70% of Healthy People 2020 goals, while reducing the number of adults initiated on statin therapy to 32.2 million. An initial 
